Table S6. Linear regression analyses of associations with change in LCBI.
| Parameter | Univariate linear regression model | Adjusted model† | ||||
|---|---|---|---|---|---|---|
| β coefficient | 95% CI | standardized β | P value | P value | ||
| Age | −0.99 | [−3.02, 1.04] | −0.14 | 0.33 | 0.82 | |
| Female | 11.21 | [−29.91, 52.34] | 0.081 | 0.59 | 0.85 | |
| ACS | −18.77 | [−58.19, 20.66] | −0.14 | 0.34 | 0.80 | |
| Current smoker | −22.72 | [−66.76, 21.33] | −0.15 | 0.30 | 0.47 | |
| Diabetes | −16.15 | [−57.13, 24.82] | −0.12 | 0.43 | 0.77 | |
| Hypertension | 32.50 | [−6.79, 71.79] | 0.24 | 0.10 | 0.24 | |
| Dyslipidemia | 7.41 | [−37.11, 51.92] | 0.050 | 0.74 | 0.55 | |
| Follow-up period | 0.084 | [−0.026, 0.19] | 0.22 | 0.13 | 0.14 | |
| Medication | ||||||
| Aspirin | −35.66 | [−102.43, 31.12] | −0.16 | 0.29 | 0.50 | |
| ACE-I/ARB | 16.49 | [−23.02, 56.00] | 0.12 | 0.41 | 0.67 | |
| Statin | −8.73 | [−53.23, 35.76] | −0.059 | 0.69 | 0.61 | |
| HIST | −5.53 | [−43.24, 32.18] | −0.044 | 0.77 | 0.83 | |
| Beta-blocker | 11.45 | [−26.85, 49.75] | 0.089 | 0.55 | 0.54 | |
| Lipids | ||||||
| T-Cho | 0.058 | [−0.34, 0.45] | 0.044 | 0.77 | 0.84 | |
| LDL-C | −0.027 | [−0.52, 0.46] | −0.017 | 0.91 | 0.53 | |
| HDL-C | 0.49 | [−1.45, 2.44] | 0.076 | 0.61 | 0.81 | |
| TG | 0.10 | [−0.14, 0.34] | 0.13 | 0.40 | 0.37 | |
| HDL-mediated cholesterol efflux capacity | ||||||
| ABCA1 CEC | 2.25 | [−4.84, 9.35] | 0.095 | 0.53 | 0.38 | |
| ABCG1 CEC | −25.40 | [−53.62, 2.82] | −0.26 | 0.08 | 0.14 | |
| SR-BI CEC | 3.44 | [−7.31, 14.19] | 0.096 | 0.52 | 0.72 | |
| HDL-mediated cholesterol efflux capacity groups | ||||||
| Higher ABCA1 CEC group | 5.95 | [−31.75, 43.66] | 0.047 | 0.75 | 0.52 | |
| Higher ABCG1 CEC group | −39.59 | [−75.42, −3.76] | −0.31 | 0.03 | 0.30 | |
| Higher SR-BI CEC group | 16.17 | [−21.26, 53.61] | 0.13 | 0.39 | 0.62 | |
| NIRS parameter | ||||||
| Baseline LCBI | −0.39 | [−0.60, −0.18] | −0.49 | <0.001 | – | |
HDL-mediated CEC groups were stratified by median value of each efflux pathway at baseline (ABCA1 CEC: 22.6%; ABCG1 CEC: 3.4%; SR-BI CEC: 10.4%; respectively). †, adjusted for baseline LCBI. A plus value of β coefficient, with concomitant P value less than 0.05, indicates that the variable is positively associated with change in coronary lipid burden; A minus value of β coefficient, with concomitant P value less than 0.05, indicates that the variable is negatively associated with change in coronary lipid burden. HDL-mediated CEC groups were stratified by median value of each efflux pathway. ABCA1 CEC, ATP-binding cassette transporter A1-mediated cholesterol efflux capacity; ABCG1 CEC, ATP-binding cassette transporter G1-mediated cholesterol efflux capacity; ACS, acute coronary syndrome; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor; CI, confidence interval; HDL, high-density lipoprotein cholesterol; HIST, high-intensity statin therapy; LCBI, lipid core burden index; LDL-C, low-density lipoprotein cholesterol; SR-BI, scavenger receptor B type I; T-Cho, total cholesterol; TG, triglyceride.